Ceredex Value Advisors’s Allergan plc AGN Stock Holding History

Ceredex Value Advisors’s Portfolio AGN Stock Details AGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-349,909	Closed	-$58.9M	–	189
2018 Q1	$58.9M	Buy	+349,909	New	+$58.7M	0.7%	64

Other funds holding AGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Ceredex Value Advisors's AGN Position: Q2 2018 in Review

Ceredex Value Advisors sold out of Allergan plc (AGN) in Q2 2018, closing a stake of 349,909 shares — an estimated $58.9M sold.

Ceredex Value Advisors first reported a position in AGN in Q1 2018 and held it in 1 quarter. The position peaked at $58.9M in Q1 2018. 1,043 funds tracked by Wall St. Rank hold AGN as of Q2 2018.

Ceredex Value Advisors reported no remaining Allergan plc position as of Q2 2018 after selling out during the quarter.
Ceredex Value Advisors sold 349,909 Allergan plc shares in Q2 2018, an estimated $58.9M.
Ceredex Value Advisors first reported a position in Allergan plc in Q1 2018 and held it in 1 quarter.
Ceredex Value Advisors's Allergan plc position peaked at $58.9M in Q1 2018.
1,043 funds tracked by Wall St. Rank held Allergan plc as of Q2 2018.

Based on Ceredex Value Advisors's 13F filing for Q2 2018, filed 13 Aug 2018.